文献速递治疗药物监测与药物基因组学抗菌药物管理

学术医学中心万古霉素AUC监测实施准备度调查

Readiness to implement vancomycin monitoring based on area under the concentration-time curve: A cross-sectional survey of a national health consortium.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

本研究向Vizient大学卫生系统联盟药学网络的124家学术医学中心发放多中心横断面电子问卷,78家完成调查(应答率62.9%)。仅23.1%(18/78)的应答机构开展基于AUC的万古霉素监测,未开展者中88.3%(53/60)不计划或不确定未来一年内转换;药师和/或医师不熟悉是最常见障碍(44/60,73.3%)。

要点

  • 仅23.1%的应答学术医学中心实施AUC-based万古霉素监测,多数仍未转换。
  • 实施AUC监测的机构中66.7%(12/18)采用两点药代动力学方法。
  • 药师与医师不熟悉是实施AUC监测最常见的障碍(73.3%)。

核心结论

  • 多数受访学术医学中心尚未实施基于AUC的万古霉素监测,且多数机构不计划或不确定在未来一年内采用该策略。

研究设计与样本

  • 多中心横断面电子问卷调查,发放至Vizient大学卫生系统联盟药学网络124家学术医学中心的药学代表,78家完成,应答率62.9%。

主要发现

  • 78家应答机构中68家(87.2%)床位约500-1000张,66家(84.6%)由药师主要负责万古霉素治疗药物监测,57家(73.1%)使用药师驱动方案。
  • 仅18家(23.1%)开展基于AUC的万古霉素监测,其中12家(66.7%)使用两点药代动力学,较少机构使用贝叶斯软件或群体药代动力学。
  • 仅开展谷浓度监测的60家机构中,53家(88.3%)不计划或不确定未来一年内转换为AUC监测。
  • 实施AUC监测机构中最常见挑战为药师和/或医师不熟悉(13/18,72.2%),该因素也是未实施机构最常见的障碍(44/60,73.3%)。

临床怎么用

  • 提示临床药学推动AUC-based万古霉素监测时,应优先开展药师与医师教育培训以消除不熟悉这一主要障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to (1) determine whether academic medical centers implemented area under the concentration-time curve (AUC)-based monitoring for vancomycin and (2) characterize perceived barriers to implementation and challenges experienced during the implementation process. METHODS: A multicenter, cross-sectional electronic survey was distributed to pharmacy representatives from 124 academic medical centers within the Vizient University Health System Consortium Pharmacy Network. RESULTS: Seventy-eight institutions completed the survey, representing a 62.9% response rate. Most institutions were approximately 500-1,000 beds (68/78, 87.2%), and pharmacists were primarily responsible for vancomycin therapeutic drug monitoring (66/78, 84.6%) using pharmacist-driven protocols (57/78, 73.1%). Less than one fourth (18/78, 23.1%) of responding academic medical centers performed AUC-based vancomycin monitoring, and the majority (12/18, 66.7%) used 2-point pharmacokinetics, with a smaller fraction using either Bayesian software or population-based pharmacokinetics. Of the responding institutions that only perform trough-based therapeutic drug monitoring (60/78, 76.9%), most (53/60, 88.3%) did not plan to or were unsure about transitioning to AUC-based monitoring within the next year. Both the most common challenge encountered (13/18, 72.2%) for institutions performing AUC-based monitoring and the most common barrier (44/60, 73.3%) to implementation of this monitoring strategy were pharmacist and/or provider unfamiliarity. CONCLUSION: The majority of surveyed academic medical centers have not yet implemented AUC-based vancomycin monitoring, and most institutions did not plan to adopt or were unsure about adopting this monitoring strategy within the next year.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Kufel WD, Seabury RW, Mogle BT, et al. Readiness to implement vancomycin monitoring based on area under the concentration-time curve: A cross-sectional survey of a national health consortium. Am J Health Syst Pharm. 2019. PMID: 31063582. doi:10.1093/ajhp/zxz070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。